Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient

Elotuzumab is the first monoclonal antibody approved for the treatment of relapsed-refractory multiple myeloma (MM) in combination with lenalidomide, an immunodulatory drug, and dexamethasone. We report on a multiply pre-treated MM patient with disease progression due to appearance of new focal lesi...

Full description

Bibliographic Details

Published in:	Diagnostics
Main Authors:	Christos Sachpekidis, Antonia Dimitrakopoulou-Strauss, Stefan Delorme, Hartmut Goldschmidt
Format:	Article
Language:	English
Published:	MDPI AG 2017-12-01
Subjects:	multiple myeloma elotuzumab lenalidomide 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) diffusion weighted imaging (DWI)
Online Access:	https://www.mdpi.com/2075-4418/7/4/61